Abstract
Congestive heart failure is a clinical syndrome characterized by symptoms of dyspnea, fatigue, and edema that most commonly result from pathophysiological events following a severe insult to the left ventricle. In recent years, a new therapeutic approach based on the pathophysiology of congestive heart failure has been established. A single agent or combination therapy with cardiac glycosides and diuretics has proven to be effective in the treatment of congestive heart failure. However, in cases of refractory cardiac failure that resist these conventional drugs, vasodilators, sympathomimetics, and myocardial metabolism activators are used in combination therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Katz AM 1986. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73:184–190.
Jacobsen JG, Smith LH Jr. 1968. Biochemistry and physiology of taurine and taurine derivatives. Physiol Rev 48:424–511.
Huxtable R, 1976. Metabolism and function of taurine in the heart. In Taurine, Huxtable R, Barbeau A, eds. New York: Raven Press, pp 99–120.
Huxtable R, Bressler R. 1974. Taurine concentrations in congestive heart failure. Science 184: 1187–1188.
Takihara K, Azuma J, Awata N, Ohta H, Hamaguchi T, Sawamura A, Tanaka Y, Kishimoto S, Sperelakis N. 1986. Beneficial effect of taurine in rabbits with chronic congestive heart failure. Am Heart J 112:1278–1284.
Sawamura A, Sperelakis N, Azuma J. 1986. Protective effect of taurine against decline of cardiac slow action potentials during hypoxia. Eur J Pharmacol 120:235–239.
Ohta H, AzumaJ, Onishi S, Awata N, Takihara K, Kishimoto S. 1986. Protective effect of taurine against isoprenaline-induced myocardial damage. Basic Res Cardiol 81:473–481.
Ohta H, Azuma J, Awata N, Hamaguchi T, Tanaka Y, Sawamura A, Kishimoto S, Sperelakis N. Mechanism of the protective action of taurine against isoprenaline-induced myocardial damage. 1988. Cardiovasc Res 22:407–413.
Hamaguchi T, Azuma J, Awata N, Ohta H, Takihara H, Harada H, Kishimoto S, Sperelakis N. Reduction of doxorubicin-induced cardiotoxicity in mice by taurine. 1988. Res Commun Chem Path Pharmacol 59:21–30.
Azuma J, Hamaguchi T, Ohta H, Takihara K, Awata N, Sawamura A, Harada H, Tanaka Y, Kishimoto S. 1987. Calcium overload-induced myocardial damage caused by isoproterenol and by adriamycin: Possible role of taurine in its prevention. In The biology of taurine, Huxtable RJ, Franconi F, Giotti A, eds. New York: Plenum Press, pp 167–179.
Takihara K, Azuma J, Awata N, Ohta H, Sawamura A, Kishimoto S, Sperelakis N. Taurine’s possible proteccive role in age-dependent response to calcium paradox. 1985. Life Sci 37: 1705–1710.
Harada H, Cusack B, Olson B, Stroo W, Azuma J, Hamaguchi T, Schaffer SW. Role for intracellular taurine pool in the Adriamycin-stressed myocardium. Biochem Pharmacol, in press.
Takihara K, Azuma J, Onishi S, Kishimoto S, Sperelakis N. Protection by taurine of calcium paradox-related damage in cardiac muscle: Its regulatory action on intracellular cation contents. 1988. Biochem Pharmacol 37:2651–2658.
Dolara P, Ledda F, Mugelli A, Mantelli L, Zilletti L, Franconi F, Giotti A. 1978. Effect of taurine on calcium, inotropism, and electrical activity of the heart. In Taurine and neurological disorders, Barbeau A, Huxtable RJ eds. New York: Raven Press, pp 151–159.
Kramer JH, Chovan JP, Schaffer SW. 1981. Effect of taurine on calcium paradox and ischemic heart failure. Am J Physiol 240:H238-H246.
Azuma J, Hasegawa H, Sawamura A, Awata N, Harada H, Ogura K, Kishimoto S. 1982. Taurine for treatment of congestive heart failure. Int J Cardiol 2:303–304.
Azuma J, Hasegawa H, Sawamura A, Awata N, Ogura K, Harada, H, Yamaura Y, Kishimoto S. 1983. Therapy of congestive heart failure with orally administered taurine. Clin Ther 5: 398–408.
Azuma J, Hasegawa H, Awata N, Sawamura A, Harada H, Ogura K, Yamauchi K, Kishimoto S. 1983. Taurine for treatment of congestive heart failure in humans. In Sulfur amino acids: Biochemical and clinical aspects, Kuriyama K, Huxtable RJ; Iwata H eds. New York: Alan R. Liss, pp 61–72.
Azuma J, Sawamura A, Awata N, Hasegawa H, Ogura K, Harada H, Ohta H, Yamauchi K, Kishimoto S, Yamagami T, Ueda E, Ishiyama T. 1983. Double-blind randomized crossover trial of taurine in congestive heart failure. Current Ther Res 34:543–553.
Azuma J, Sawamura A, Awata N, Ohta H, Hamaguchi T, Harada H, Takihara K, Hasegawa, H, Yamagami T, Ishiyama T, Iwata H, Kishimoto S. 1985. Therapeutic effect of taurine in congestive heart failure: A double-blind crossover trial. Clin Cardiol 8:276–282.
Criteria Committee of the New York Heart Association. 1973. In Nomenclature and criteria for diagnosis of disease of the heart and blood vessels, 7th ed. Boston: Little, Brown.
Colucci, WS., Wright RF, Braunwald E. 1986. New positive inotropic agents in the treatment of congestive heart failure: Mechanisms of action and recent clinical developments. N Engl J Med 314:290–299.
Colucci WS, Wright RF, Braunwald E. 1986. New positive inotropic agents in the treatment of congestive heart failure: Mechanisms of action and recent clinical developments. N. Engl J Med 314:349–358.
Braunmald E, Colucci W. 1984. Evaluating the efficacy of new inotropic agents. J Am Coll Cardiol 3:1570–1574.
Franconi F, Stendardi I, Matucci R, Failli P, Bennardini F, Antonini G, Giotti A. 1984. Inotropic effect of taurine in guinea-pig ventricular strips. Eur J Pharmacol 102:511–514.
Sawamura A, Azuma J, Harada H, Hasegawa H, Ogura K, Sperelakis N, Kishimoto S 1983. Protection by oral pre-treatment with taurine against the negative inotropic effects of low-calcium medium on isolated perfused chick heart. Cardiovasc Res 17:620–626.
Franconi F, Giotti A, Manzini S, Martini F, Stendardi I, Zilletti L. 1982. Observations on the action of taurine at arterial and cardiac levels. In Taurine in nutrition and neurology, Huxtable R, Pasantes-Morales H, eds. New York: Plenum Press, pp. 181–190.
Franconi F, Martini F, Stendardi I, Matucci R, Zilletti L, Giotti A. 1982. Effect of taurine on calcium levels and contractility in guinea-pig ventricular strips. Biochem Pharmacol 31: 3181–3186.
Awata N, Azuma J, Hamaguhi T, Tanaka Y, Ohta H, Takihara K, Harada H, Sawamura A, Kishimoto S. Acute haemodynamic effect of taurine on the hearts in vivo with normal and depressed myocardial function. 1987. Cardiovasc Res 21:241–247.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Acacdemic Publishers, Boston/Dordrecht/London
About this chapter
Cite this chapter
Azuma, J. et al. (1989). Clinical Evaluation of Taurine in Congestive Heart Failure—A Double-Blind Comparative Study Using CoQ10 as a Control Drug. In: Iwata, H., Lombardini, J.B., Segawa, T. (eds) Taurine and the Heart. Developments in Cardiovascular Medicine, vol 93. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1647-3_6
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1647-3_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8915-9
Online ISBN: 978-1-4613-1647-3
eBook Packages: Springer Book Archive